KDR and neoplasm: Tumor cells may acquire secondary mutations in the target receptor kinases or activate bypass signaling pathways—such as the fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) axes—that effectively circumvent the inhibitory actions on VEGFR, FGFR, and CSF1R [40,41].